Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Exercise  COVID-19 treatment studies for Exercise  C19 studies: Exercise  Exercise   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Exercise for COVID-19: real-time meta analysis of 48 studies
Covid Analysis, December 2022
https://c19early.org/exmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hamer 28% 0.72 [0.61-0.87] hosp. n/a n/a Improvement, RR [CI] Treatment Control Hamer 34% 0.66 [0.55-0.79] hosp. n/a n/a Brawner 74% 0.26 [0.11-0.58] hosp. n/a n/a Tret'yakov 98% 0.02 [0.00-0.27] severe case 0/27 53/266 Gao -105% 2.05 [1.39-3.02] cases case control Ho 35% 0.65 [0.48-0.89] hosp. 213/123,588 59/14,887 Halabchi 89% 0.11 [0.01-1.46] death 0/249 79/4,445 Halabchi 28% 0.72 [0.51-0.98] hosp. 30/249 878/4,445 Zhang 26% 0.74 [0.48-1.14] death n/a n/a Zhang 18% 0.82 [0.69-0.96] cases n/a n/a Li 81% 0.19 [0.05-0.74] severe case n/a n/a per SD increase Li 56% 0.44 [0.18-1.07] hosp. n/a n/a per SD increase Tavakol 69% 0.31 [0.10-1.02] severe case 3/64 19/124 Yates 45% 0.55 [0.38-0.79] death 72/163,912 62/30,119 Yates 47% 0.53 [0.43-0.66] severe case 291/163,912 180/30,119 Holt 17% 0.83 [0.63-1.09] cases n/a n/a Cho 53% 0.47 [0.26-0.87] death case control Cho 10% 0.90 [0.86-0.95] cases case control Sallis 59% 0.41 [0.22-0.76] death 11/3,118 170/6,984 Sallis 42% 0.58 [0.40-0.85] ICU 32/3,118 195/6,984 Sallis 53% 0.47 [0.38-0.58] hosp. 99/3,118 732/6,984 Christensen 63% 0.37 [0.16-0.85] death 543 (n) 529 (n) Christensen 23% 0.77 [0.52-1.15] cases 55/543 77/529 Latorre-Román 76% 0.24 [0.05-1.04] hosp. n/a n/a Latorre-Román 87% 0.13 [0.01-1.17] hosp. n/a n/a Marcus 42% 0.58 [0.48-0.71] symp. case 240/10,627 134/3,708 Yuan 91% 0.09 [0.01-1.65] death 0/61 6/103 Yuan 70% 0.30 [0.09-0.92] severe case 3/61 26/103 Brandenburg -6% 1.06 [0.23-4.79] hosp. 102 (n) 39 (n) Brandenburg 78% 0.22 [0.05-1.02] hosp. 177 (n) 34 (n) Brandenburg 64% 0.36 [0.13-0.98] hosp. 97 (n) 34 (n) Brandenburg 35% 0.65 [0.28-1.48] severe case 102 (n) 39 (n) Brandenburg 24% 0.76 [0.28-2.04] severe case 52 (n) 34 (n) Bielik 30% 0.70 [0.40-1.21] mod. case 775 (n) 365 (n) Bielik -9% 1.09 [0.69-1.73] cases 775 (n) 365 (n) af Geijerstam 50% 0.50 [0.31-0.81] death 318,902 (n) 336,271 (n) af Geijerstam 40% 0.60 [0.46-0.80] ICU 318,902 (n) 336,271 (n) af Geijerstam 27% 0.73 [0.64-0.83] hosp. 318,902 (n) 336,271 (n) Lee 74% 0.26 [0.07-0.99] death 2/11,072 32/41,293 Lee 58% 0.42 [0.19-0.91] severe case 39/11,072 273/41,293 Lee 16% 0.84 [0.73-0.98] cases 291/11,072 1,293/41,293 Maltagliati 52% 0.48 [0.25-0.87] hosp. n/a n/a Baynouna AlKetbi 98% 0.01 [0.00-0.44] death n/a n/a Ahmadi 30% 0.70 [0.54-0.89] death 160/232,613 112/95,221 Nguyen 20% 0.80 [0.72-0.88] symp. case 904/2,836 483/1,111 Lin 47% 0.53 [0.12-2.33] cases n/a n/a de Souza 73% 0.27 [0.07-1.06] ventilation 3/611 6/327 de Souza 34% 0.66 [0.43-0.99] hosp. 49/611 42/327 Mohsin 19% 0.81 [0.66-0.99] severe case 86/258 224/544 Mohsin -1% 1.01 [0.88-1.15] severe case 290/698 224/544 Ekblom-Bak 48% 0.52 [0.30-0.92] severe case n/a n/a Lengelé 74% 0.26 [0.07-0.80] cases 23/229 4/12 Saadeh 9% 0.91 [0.56-1.43] symp. case 362 (n) 225 (n) Saadeh 4% 0.96 [0.62-1.43] symp. case 362 (n) 225 (n) Hamrouni 29% 0.71 [0.55-0.92] death 138/106,006 109/47,827 Huang 47% 0.53 [0.23-1.22] severe case 7/74 16/90 Huang 8% 0.92 [0.30-2.85] severe case 3/23 20/141 Huang 66% 0.34 [0.17-0.70] cases n/a n/a Hamdan 16% 0.84 [0.49-1.39] hosp. 22/128 37/172 Steenkamp 42% 0.58 [0.50-0.68] death 29,469 (n) 13,366 (n) Steenkamp 45% 0.55 [0.47-0.64] ventilation 29,469 (n) 13,366 (n) Steenkamp 41% 0.59 [0.52-0.66] ICU 29,469 (n) 13,366 (n) Steenkamp 34% 0.66 [0.63-0.70] hosp. 29,469 (n) 13,366 (n) Gilley -42% 1.42 [0.60-3.35] cases 172/1,917 5/79 Almansour 6% 0.94 [0.40-1.47] cases 35/71 38/71 Beydoun 43% 0.57 [0.32-1.01] cases 1,710 (n) 448 (n) Beydoun 62% 0.38 [0.18-0.78] cases 672 (n) 448 (n) Salgado-Aranda 83% 0.17 [0.05-0.56] death 4/223 41/297 Paul 38% 0.62 [0.30-1.20] no recov. n/a n/a Paul 4% 0.96 [0.53-1.63] no recov. n/a n/a Kontopoulou 66% 0.34 [0.24-0.47] recov. time 42 (n) 24 (n) Kontopoulou 67% 0.33 [0.24-0.46] no recov. 42 (n) 24 (n) Malisoux 63% 0.37 [0.14-0.98] progression 115 (n) 108 (n) Malisoux 52% 0.48 [0.18-1.29] progression 116 (n) 108 (n) Malisoux 43% 0.57 [0.20-1.58] progression 113 (n) 108 (n) Antunes 80% 0.20 [0.03-1.41] ICU 1/14 9/25 Antunes 40% 0.60 [0.19-1.84] misc. 3/14 9/25 Antunes 73% 0.27 [0.07-1.05] misc. 2/14 13/25 Antunes 43% 0.57 [0.34-0.95] hosp. time 14 (n) 25 (n) Antunes 26% 0.74 [0.58-0.95] misc. 14 (n) 25 (n) Tsuzuki 56% 0.44 [0.36-0.52] severe case 3,340 (n) 1,528 (n) Reis 41% 0.59 [0.26-1.26] hosp. 9/241 29/305 Pływaczewska-J.. 11% 0.89 [0.72-1.11] m/s case 490 (n) 1,357 (n) Pływaczewska-J.. 14% 0.86 [0.66-1.11] PASC 389 (n) 1,128 (n) Pitanga 33% 0.67 [0.45-1.01] cases 1,469 (n) 1,552 (n) Green 42% 0.58 [0.53-0.63] cases 1,267/11,144 16,198/101,931 Exercise COVID-19 outcomes c19early.org/ex Dec 2022 Favors exercise Favors inactivity
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit